your initial deposit *subject to change and depends on individual circumstances.
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange.
Oxford BioMedica's products use genes as the mediators of a...
Oxford Biomedica shares rise on positive review findingsAugust 08 2012, 9:31am
The studies into RetinoStat and StarGen for the treatment of macular degeneration and Stargardt disease were reviewed by the Data Safety Monitoring Board (DSMB) - an independent panel of specialists.
Both were designed and developed by the firm using its proprietary LentiVector gene delivery technology.
In the ongoing phase 1 RetinoStat study for "wet" age related macular degeneration, nine patients have been treated so far (of 18) at each of three dose levels and no serious "adverse events" related to RetinoStat or its administration were found. The DSMB gave support to proceed to the final patient cohort.
In the phase I/IIa clinical study of StarGen, eight patients have been treated so far (of up to 28) and DSMB support has been gained to proceed to the third patient cohort.
Chief executive John Dawson told investors: "The continued progress of our ophthalmology portfolio, supported by another positive DSMB review, is encouraging - particularly given that early RetinoStat data demonstrate sustained therapeutic protein expression in the eye following a single administration.
"The favourable safety profile of our novel ocular gene therapies further supports the wider LentiVector platform safety package with over 33 patients treated to date across the ocular and Parkinson's disease programmes."
Age-related macular degeneration (AMD) is a major cause of blindness affecting an estimated 25 to 30 million people worldwide.
Stargardt disease is the most common juvenile degenerative retinal disease which affects approximately 80-100,000 patients in the US and Europe.